Surrogate Endpoint For Drug-Eluting Stent Trials Hotly Contested AT TCT

FDA, industry and academia should pool data to determine whether late lumen loss is a viable surrogate endpoint for drug-eluting stent trials, according to CDRH Division of Cardiovascular Devices Director Bram Zuckerman, MD